Newsroom
Sorted by: Latest
-
Bank of New York Mellon UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- As Agent Bank, please be advised of the following rate determined on: 8/28/2026 Issue ¦ National Grid Electricity Transmission - Series 22 GBP 75,000,000 FRN Due 28 Sep 2035 ISIN Number ¦ XS0230845207 ISIN Reference ¦ 23084520 Issue Nomin GBP ¦ 75000000 Period ¦ 9/28/2026 to 3/28/2027 Payment Date 3/30/2027 Number of Days ¦ 181 Rate ¦ 4.515586 Denomination GBP ¦ 50000 ¦ 75000000 ¦ Amount Payable per Denomination ¦ 1128.9 ¦ 1693344.82 ¦ Bank...
-
Fujirebio erweitert den Zugang zu neurologischen Blutuntersuchungen in Brasilien dank der ANVISA-Zulassung für Lumipulse® G NfL Blood und Lumipulse G pTau 217 Plasma
GENT, Belgien & TOKIO--(BUSINESS WIRE)--Die H.U. Group Holdings Inc. und ihre hundertprozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass die brasilianische Gesundheitsaufsichtsbehörde (ANVISA) die Marktzulassung für die Tests „Lumipulse G NfL Blood“ und „Lumipulse G pTau 217 Plasma“ zur Verwendung auf der vollautomatischen LUMIPULSE® G-Immunoassay-Plattform in Brasilien erteilt hat. „Die Zulassung der Tests Lumipulse G NfL Blood und Lumipulse G pTau 217 Plasma durch die ANVISA st...
-
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and...
-
Samenvatting: Fujirebio breidt toegang tot neurologietesten gebaseerd op bloed in Brazilië uit met een handelsvergunning van ANVISA voor Lumipulse® G NfL Blood en Lumipulse G pTau 217 Plasma
GENT, België & TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. en zijn dochteronderneming Fujirebio volledig in handen van de holding, maakten vandaag bekend dat ANVISA, de Braziliaanse toezichthoudende gezondheidsinstantie, een handelsvergunning heeft toegekend voor de Lumipulse G NfL Blood en Lumipulse G pTau 217 Plasma-testen voor gebruik op de volledig geautomatiseerde LUMIPULSE® G immunoassay-platform in Brazilië. “De vergunning van ANVISA voor de Lumipulse G NfL Blood en Lumipulse G pTau...
-
Wealth.com Brings Estate and Tax Planning Into Claude for Financial Advisors
NEW YORK--(BUSINESS WIRE)--Wealth.com, the leading estate and tax planning platform for wealth management firms, today announced it is a launch partner for Claude for Financial Advisors. Estate and tax planning demand a level of precision that few advisor workflows do. Questions about what a trust provides, who holds authority under a health care directive or what the financial impact of a tax strategy would be must be grounded in executed documents, applicable law and validated quantitative an...
-
The Estée Lauder Companies Announces Partnership with Profound to Expand AI Visibility Across Its Global Brand Portfolio
NEW YORK--(BUSINESS WIRE)--The Estée Lauder Companies Inc. (NYSE: EL) today announced a global strategic partnership with Profound, the category-defining AI marketing platform, advancing its ambition to be prestige beauty’s leader in AI-native discovery. The partnership will provide the company with visibility into how its full portfolio of brands is represented across leading generative AI platforms, as well as opportunities to optimize that representation. This partnership establishes the com...
-
Fujirebio élargit l'accès aux tests neurologiques basés sur le sang au Brésil avec l'autorisation de mise sur le marché de l'ANVISA pour Lumipulse® G NfL Blood et Lumipulse G pTau 217 Plasma
GAND, Belgique, et TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. et sa filiale en exclusivité Fujirebio annoncent aujourd'hui que l'Agence brésilienne de réglementation sanitaire (ANVISA) a accordé l'autorisation de mise sur le marché pour les tests Lumipulse G NfL Blood et Lumipulse G pTau 217 Plasma, destinés à être utilisés sur la plateforme d'immunoanalyse entièrement automatisée LUMIPULSE® G au Brésil. « L'autorisation de l'ANVISA pour les tests Lumipulse G NfL Blood et Lumipulse G pTau...
-
Fujirebio amplía el acceso a pruebas neurológicas en sangre en Brasil con la autorización de comercialización de ANVISA para Lumipulse® G NfL Blood y Lumipulse G pTau 217 Plasma
GENT (Bélgica) y TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. y su filial de propiedad exclusiva, Fujirebio, anunciaron hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA) ha otorgado la autorización de comercialización para los ensayos Lumipulse G NfL Blood y Lumipulse G pTau 217 Plasma, destinados a su uso en la plataforma de inmunoensayos totalmente automatizada LUMIPULSE® G en Brasil. “La autorización de ANVISA para los ensayos Lumipulse G NfL Blood y Lumipulse G pTau...
-
Avangrid Expands AI Adoption to Strengthen Utility Operations and Customer Experience
ORANGE, Conn.--(BUSINESS WIRE)--Building on Iberdrola’s global leadership in AI adoption, Avangrid is applying practical, employee-centered AI tools across the business....
-
Charles Schwab and Anthropic to Bring Claude to Independent Registered Investment Advisors
WESTLAKE, Texas & HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--Schwab Advisor Services, Charles Schwab's business supporting the growth and success of independent registered investment advisors (RIAs), today announced it is working with Anthropic to bring Claude for Financial Advisors, Anthropic's new offering, directly to the 16,000-plus independent RIAs Schwab serves. Claude for Financial Advisors is designed to support the work that advisors complete throughout a day — from prepping for a clie...